Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Diastika Biotekindo TbkISX:CHEK +1.50% Buyback Yield % is 0.00 as of Aug. 07, 2026. The stock has 1 warning sign investors should review. Among 39 Medical Distribution companies, PT Diastika Biotekindo Tbk ranks worse than 2564100% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diastika Biotekindo Tbk Buyback Yield % Chart
PT Diastika Biotekindo Tbk Annual Data
Trend
Buyback Yield %
PT Diastika Biotekindo Tbk Semi-Annual Data
Buyback Yield %
ISX:CHEK vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Distribution subindustry, PT Diastika Biotekindo Tbk's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Diastika Biotekindo Tbk Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Diastika Biotekindo Tbk's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where PT Diastika Biotekindo Tbk's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diastika Biotekindo Tbk (ISX:CHEK) has a Buyback Yield % of 0.00 as of Aug. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PT Diastika Biotekindo Tbk and its competitors. According to the industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 39 companies in the Medical Distribution industry.
Is PT Diastika Biotekindo Tbk's Buyback Yield % too high?
PT Diastika Biotekindo Tbk's current Buyback Yield % is 0.00. Based on the distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 39 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does PT Diastika Biotekindo Tbk's Buyback Yield % compare to ABT and SYK?
According to the Medical Distribution industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 39 companies for Buyback Yield %. This places PT Diastika Biotekindo Tbk in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PT Diastika Biotekindo Tbk and its competitors. PT Diastika Biotekindo Tbk's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diastika Biotekindo Tbk stock overvalued right now?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For PT Diastika Biotekindo Tbk (ISX:CHEK), the current Buyback Yield % is 0.00 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressJalan Rawagelam V, Kawasan Industri Pulogadung, Block L, No. Kav 11-13, Gedung Etana Lantai 3, Desa/Kelurahan Jatinegara, Kec. Cakung, Kota Adm. Jakarta Timur, Jakarta, IDN, 13930
PT Diastika Biotekindo Tbk is engaged in providing medical and laboratory equipment solutions in Indonesia. It is engaged in the wholesale trading of laboratory equipment, pharmaceutical products, and medical devices for human use. The company is also involved in wholesale trading of radioactive substances and ionizing radiation generators, and undertakes activities related to the testing and/or calibration of medical devices, as well as the inspection of healthcare facilities and infrastructure. Its product offerings mainly include devices like hematology analyzer, pipette, hemoglobin testing system, etc. The company's operating segments are: Diagnostics Group, which generates the maximum revenue, and Life Sciences Group. Geographically, all of its revenue is derived from Indonesia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:CHEK has been successfully added to your 
